Literature DB >> 17283406

Clinical significance of circulating vascular endothelial growth factor in dogs with mammary gland tumors.

Yuka Kato1, Kazushi Asano, Toshiaki Mogi, Kenji Kutara, Kenji Teshima, Kazuya Edamura, Shigehisa Tsumagari, Atsuhiko Hasegawa, Shigeo Tanaka.   

Abstract

Increase in circulating vascular endothelial growth factor (VEGF) is suggested as a prognostic indicator in human patients with malignant tumors. The purpose of this study was to evaluate the clinical significance of circulating VEGF in dogs with mammary gland tumors (MGT). Both plasma and serum VEGF were significantly higher in dogs with MGT when compared with those in the healthy dogs. In dogs with MGT, the plasma and serum VEGF of the malignant group increased significantly compared with those of the benign group. Additionally, there was a significant difference between the plasma and serum VEGF in the groups with postoperative metastasis and no metastasis. Circulating VEGF is expected to be clinically available for the determination of prognosis in canine MGT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283406     DOI: 10.1292/jvms.69.77

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  4 in total

1.  Plasma free amino acid profiles of canine mammary gland tumors.

Authors:  Kazuo Azuma; Tomohiro Osaki; Takeshi Tsuka; Tomohiro Imagawa; Saburo Minami; Yoshiharu Okamoto
Journal:  J Vet Sci       Date:  2012-12       Impact factor: 1.672

2.  Serum vascular endothelial growth factor in dogs with various proliferative diseases.

Authors:  Hiro Horikirizono; Kumiko Ishigaki; Keigo Iizuka; Kei Tamura; Naoki Sakurai; Kazuyuki Terai; Tatsuya Heishima; Orie Yoshida; Kazushi Asano
Journal:  J Vet Med Sci       Date:  2022-04-04       Impact factor: 1.105

3.  VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model.

Authors:  R Patruno; N Arpaia; C D Gadaleta; L Passantino; N Zizzo; A Misino; N M Lucarelli; A Catino; P Valerio; D Ribatti; G Ranieri
Journal:  J Cell Mol Med       Date:  2008-04-18       Impact factor: 5.310

4.  Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines.

Authors:  Fulya Ustun-Alkan; Tülay Bakırel; Oya Üstüner; Ceren Anlas; Suzan Cinar; Funda Yıldırım; Aydın Gürel
Journal:  J Vet Res       Date:  2021-07-24       Impact factor: 1.744

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.